ANIK Anika Therapeutics Inc.

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end 2020 financial results after the close of the market on Thursday, March 4, 2021 and hold its investor conference call and webcast on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10012940. A live audio webcast will be available in the section of Anika's website, . An accompanying slide presentation also can be accessed via the Anika investor relations website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

 (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit .

For Investor Inquiries:

Anika Therapeutics, Inc.

Mark Namaroff, 781-457-9287

Executive Director, Investor Relations and Corporate Communications



EN
09/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

Anika Reports Fourth Quarter and Year-End 2023 Financial Results Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preserva...

 PRESS RELEASE

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the A...

 PRESS RELEASE

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on W...

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024 BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-888-886-7786 (toll-fr...

 PRESS RELEASE

Anika Highlights Its Recently Launched Integrity™ Implant System and R...

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting Announcing the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS Focusing on its full Regenerative, Sports Medicine and Arthrosurface Joint Solutions portfolio addressing the over $2.0 billion U.S. rotator cuff market1 BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ANIK), a global joint preserva...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch